skip to content
Primary navigation


Drug - Reyvow™ (lasmiditan) [Eli Lilly and Company]

July 2020

Therapeutic area - Antimigraine Agents, Other

Initial approval criteria:

  • Patient must be ≥ 18 years of age; AND
  • Patient must have a diagnosis of migraine, with or without aura; AND
  • Patient must not have headache frequency ≥ 15 headache days per month; AND
  • Patient must not have hypersensitivity to any component of the product; AND
  • Patient must not have severe hepatic impairment (Child-Pugh C); AND
  • Patient must have tried and failed to at least one of the following: NSAID, non-opioid analgesic, acetaminophen OR caffeinated analgesic combination; AND
  • Patient must have tried and failed, or have contraindication to, ≥ 2 preferred triptans; AND
  • Prescriber must attest to all of the following:
    • Patient has been cautioned about potential of Reyvow to cause sedation, alone or in combination of other CNS depressants or alcohol; AND
    • Patient has been educated about need to refrain from driving or operating machinery for ≥ 8 hours after dose; AND
    • Patient has been advised about the increased risk of serotonin syndrome when Reyvow is used in combination with other drugs (e.g., SSRIs, SNRIs, TCAs, MAO inhibitors, trazodone, etc.); AND
    • If applicable, provider has completed a review of patient’s adherence of any medication used to prevent migraine and address any patient’s adherence issue.

Renewal criteria:

  • Patient must continue to meet the above criteria; AND
  • Patient has not had any treatment-limiting adverse effects (e.g., central nervous system depression, sedation, serotonin syndrome, medication overuse headache); AND
  • Patient must demonstrate resolution in headache pain or reduction in headache severity, as assessed by prescriber.

Quantity limits:

  • 4 doses per 30 days
  • Any request for quantities exceeding those recommended by the FDA will not be approved

Background information: 

Reyvow FDA-approved label states:

  • No more than one dose should be taken in 24 hours 
  • A second dose of Reyvow has not been shown to be effective for the same migraine attack.
  • The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.


MHCP Provider Call Center 651-431-2700 or 1-800-366-5411

back to top